Colección SciELO Chile

Departamento Gestión de Conocimiento, Monitoreo y Prospección
Consultas o comentarios: productividad@anid.cl
Búsqueda Publicación
Búsqueda por Tema Título, Abstract y Keywords



Osteosarcoma as a GES-Listed Pathology: 7-Year Experience at a National Reference Center Osteosarcoma como patología GES. Experiencia de 7 años en Centro de Referencia Nacional
Indexado
Scopus SCOPUS_ID:85200148190
SciELO S0034-98872023000700880
DOI 10.4067/S0034-98872023000700880
Año 2023
Tipo artículo de investigación

Citas Totales

Autores Afiliación Chile

Instituciones Chile

% Participación
Internacional

Autores
Afiliación Extranjera

Instituciones
Extranjeras


Abstract



Background: Osteosarcoma (OS) is the most frequent malignant primary bone tumor. The explicit health guarantee (GES) plan in Chile, a law that guarantees diagnosis, treatment, and rehabilitation, incorporated OS in 2014. Objectives: To describe the characteristics of the population over 15 years, with a histopathological diagnosis of OS, to define survival rate and complications, and to identify variables that affect these outcomes. Methods: A retrospective study from 2014 to 2020, including all patients affiliated with the public health system diagnosed with OS, with histological confirmation. From clinical records, we extracted demographic data, anatomical OS location, histopathological findings, admission stage, presence of metastases, treatment, complications, and survival. We determined prognostic factors by multivariate analysis. Results: 133 patients, 58.8% men, the average age was 31 years, and the most frequent location was the distal femur (34.9%). 56.4% of the patients were admitted in Enneking stage IIB, and 36.4% presented metastasis at admission. 14.3% presented complications, the most frequent periprosthetic infection (6 cases). 16% of patients evolved with local recurrence. The multivariate model showed that age and metastases at admission constitute independent prognostic variables, with a hazard ratio of 1.017 for age (p = 0.016) and 3.13 for metastases (p = 0.0000). In the subgroup analysis, patients without metastases at diagnosis had a 5-year survival of 54% versus 11% for the group with metastases. Adjusting for age, the 5-year survival for the non-metastatic and metastatic groups was 73% and 22%, respectively. Conclusion: This is our country's first demographic description study of patients with OS. In our series, the age of presentation and the presence of metastases at admission were factors that significantly affect prognosis. When adjusting for age, the survival percentages are comparable to those reported in other international centers specialized in sarcomas.

Revista



Revista ISSN
Revista Médica De Chile 0034-9887

Métricas Externas



PlumX Altmetric Dimensions

Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:

Disciplinas de Investigación



WOS
Medicine, General & Internal
Scopus
Medicine (All)
SciELO
Health Sciences

Muestra la distribución de disciplinas para esta publicación.

Publicaciones WoS (Ediciones: ISSHP, ISTP, AHCI, SSCI, SCI), Scopus, SciELO Chile.

Colaboración Institucional



Muestra la distribución de colaboración, tanto nacional como extranjera, generada en esta publicación.


Autores - Afiliación



Ord. Autor Género Institución - País
1 Cruz, Orlando Wevar - Instituto Traumatológico - Chile
1 Wevar Cruz, Orlando - Instituto Traumatológico - Chile
2 Diegues, Óscar Ceballos - Instituto Traumatológico - Chile
2 Ceballos Diegues, Óscar - Instituto Traumatológico - Chile
3 Jiménez, Jorge Cabrolier - Instituto Traumatológico - Chile
3 Cabrolier Jiménez, Jorge - Instituto Traumatológico - Chile
4 Soto, Ricardo Tolosa - Instituto Traumatológico - Chile
4 Tolosa Soto, Ricardo - Instituto Traumatológico - Chile

Muestra la afiliación y género (detectado) para los co-autores de la publicación.

Financiamiento



Fuente
Sin Información

Muestra la fuente de financiamiento declarada en la publicación.

Agradecimientos



Agradecimiento
Sin Información

Muestra la fuente de financiamiento declarada en la publicación.